Harmaline — Hermetica Encyclopedia
Named Bioactive Compounds · Compound

Harmaline

Provisional Moderate Scorealkaloid

Hermetica Superfood Encyclopedia

Evidence review status: unreviewed

Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.

Review flags: AWAITING_SEMANTIC_VALIDATION

Provisional Summary

Harmaline is a beta-carboline alkaloid that acts as a potent MAO-A inhibitor with an IC50 of 3-5 nM, potentially supporting mood regulation by increasing serotonin and dopamine levels. This alkaloid also demonstrates vasorelaxant properties through calcium channel modulation and may enhance cognitive function via cholinergic system activation.

Screened PMID Records
Reported Benefits
Pending
Synergy Review
At a Glance
CategoryNamed Bioactive Compounds
GroupCompound
Public Score StatusProvisional Moderate
Primary Keywordharmaline benefits
Harmaline close-up macro showing natural texture and detail — rich in mao-a inhibitor, hallucinogenic, neuroprotective
Harmaline — botanical close-up

Origin & History

Harmaline growing in Mediterranean — natural habitat
Natural habitat

Harmaline is a naturally occurring β-carboline alkaloid primarily extracted from Syrian rue (Peganum harmala) seeds native to the Mediterranean and Central Asia, and from Banisteriopsis caapi vines used in South American ayahuasca brews. It is typically extracted using acid-base methods with methanol or ethanol solvents, yielding a crystalline powder with the formula C13H14N2O.

Harmaline-rich Peganum harmala seeds have been used for approximately 3,000 years in Middle Eastern, North African, and Central Asian traditional medicine systems for depression, pain, and spiritual purposes (PMID: 23107733). In Amazonian shamanism, Banisteriopsis caapi containing harmaline has been central to ayahuasca healing rituals for over 2,000 years, primarily for psychological and spiritual ailments (PMID: 38363085).Traditional Medicine

Research Narrative (Provisional)

Direct human clinical trials on pure harmaline are limited, with most evidence from a Phase 1 trial of harmine HCl (n=25) showing doses up to 200mg well-tolerated with mild GI/neurological effects (PMID: 39301926). A 90-day rat toxicity study of Thai ayahuasca extract containing harmaline established a NOAEL of 45 mg/kg/day with reversible tremors at higher doses but no organ damage (PMID: 30970283). No large RCTs or meta-analyses exist specifically for harmaline therapeutic outcomes.

Preparation & Dosage

Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.

Nutritional Profile

Harmaline (C₁₂H₁₂N₂O; MW 212.25 g/mol) is a dihydro-β-carboline alkaloid, not a nutritional substance per se, but a bioactive compound found naturally in specific plant sources. It has no macronutrient value (no protein, fat, carbohydrate, or fiber contribution at pharmacologically relevant doses). Key details: • Primary natural sources: Seeds of Peganum harmala (Syrian rue) containing ~2–7% total β-carboline alkaloids by dry weight, of which harmaline typically constitutes ~33–56% (approximately 1–4% of seed dry weight); also found in trace amounts in Banisteriopsis caapi vine bark (~0.03–0.08% dry weight, secondary to harmine). • Chemical class: 7-Methoxy-1-methyl-4,9-dihydro-3H-β-carboline; differs from harmine by saturation of the C-3,4 bond in the pyridine ring, resulting in distinct pharmacokinetic and potency profiles. • Bioactive concentration benchmarks: MAO-A inhibition IC₅₀ ~3–5 nM (reversible, competitive); MAO-B inhibition IC₅₀ ~100 µM (highly selective for MAO-A, selectivity ratio ~20,000–30,000-fold); acetylcholinesterase inhibition IC₅₀ ~30–50 µM (moderate). • Bioavailability notes: Oral bioavailability in rodent models estimated at ~20–50% due to significant first-pass hepatic metabolism; primary metabolic pathway is O-demethylation by CYP2D6 and CYP1A2 to harmol and harmalol, followed by glucuronidation and sulfation; plasma half-life approximately 1–3 hours in animal models; crosses the blood-brain barrier readily due to lipophilicity (LogP ~1.6–2.0). • Co-occurring bioactives in P. harmala seeds: Harmine (~2–5% dry weight), harmalol (~0.5–1%), tetrahydroharmine (trace), vasicine/deoxyvasicine (quinazoline alkaloids, ~0.5–1%), plus minor flavonoids and fatty acids in seed oil fraction. • Micronutrient context of whole P. harmala seeds (not harmaline isolate): Seeds contain minerals including potassium, calcium, magnesium, iron, and zinc in modest amounts, plus ~15–20% crude protein, ~10–15% lipid (linoleic and oleic acid predominant), and ~20–25% crude fiber, though these are nutritional properties of the seed matrix rather than harmaline itself. • Solubility: Sparingly soluble in water (~1.5 mg/mL at pH 7); enhanced solubility at acidic pH as hydrochloride salt (~50 mg/mL); freely soluble in ethanol, methanol, and DMSO. • Stability: Sensitive to light (UV degradation of the indole chromophore); relatively stable at acidic pH and under dark storage conditions at room temperature.

Reported Mechanism (Provisional)

Mechanism of Action

Harmaline selectively inhibits monoamine oxidase A (MAO-A) with high potency (IC50 3-5 nM), preventing the breakdown of serotonin, dopamine, and norepinephrine neurotransmitters. The compound activates the cholinergic system by increasing choline acetyltransferase (ChAT) activity more effectively than harmine. Additionally, harmaline induces vasorelaxation through calcium channel blockade and modulation of intracellular calcium signaling pathways.

Clinical Narrative (Provisional)

Research on harmaline is primarily limited to preclinical studies and mechanism-based investigations. Rodent models demonstrate superior cognitive enhancement compared to harmine through increased ChAT activity (PMC5932362). MAO-A inhibition data comes from enzyme assays showing potent inhibitory activity at nanomolar concentrations. Human clinical trials specifically evaluating harmaline's therapeutic effects are lacking, making safety and efficacy profiles in humans largely unknown.

Also Known As

4,9-dihydro-7-methoxy-1-methyl-3H-pyrido[3,4-b]indole1-Methyl-7-methoxy-3,4-dihydro-β-carbolineDihydroharmineBanisterineTelepathineYageineHarmal alkaloid

Explore the Full Encyclopedia

Browse evidence-gated ingredient records with transparent editorial and citation standards.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
From the Hermetica Research Desk

Research updates — and 25% off your first order

Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.

Educational content only — not medical advice.